Subject non compliance (or product failure?) [Study As­sess­ment]

posted by Helmut Homepage – Vienna, Austria, 2020-07-16 14:30 (675 d 06:51 ago) – Posting: # 21714
Views: 1,802

Hi Loky do,

» if a subject didn't have any evaluable concentrations for only test product all intervals are BLQ and according to our SOPs and SAP, the BLQ is considered "zeros", could be excluded from PK …

What does you protocol say? See also this recent thread.
Even if the outcome of investigations is negative, likely it would ring the alarm bells of regulators, esp. since you found no concentrations after the test product. What if it was a product failure (example: bad coating of a gastro-resistant PPI)? Regulators are more relaxed about the reference product since it “works” in clinical practice despite occasional failures. The EMA accepts exclusion in exceptional cases:(my emphases)

In your case (test only) cards are stacked against you.

» … and statistical analysis?

$$\lim_{x \to 0} \log x=-\infty.$$For simplicity we can say that \(\small{\log 0}\) is undefined. Hence, the common analysis based on log transformed PK metrics without excluding the subject is not possible at all.

Dif-tor heh smusma 🖖 [image]
Helmut Schütz

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
 Admin contact
22,091 posts in 4,630 threads, 1,566 registered users;
online 37 (0 registered, 37 guests [including 29 identified bots]).
Forum time: Sunday 21:22 CEST (Europe/Vienna)

Competence, like truth, beauty and contact lenses,
is in the eye of the beholder.    Laurence J. Peter

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz